Cimetidine, a Histamine H2Receptor Antagonist, Occupies Androgen Receptors*
| Autor: | John W. Funder, Julie E. Mercer |
|---|---|
| Rok vydání: | 1979 |
| Předmět: |
Male
Receptors Steroid medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism medicine.medical_treatment Clinical Biochemistry Pharmacology Kidney Binding Competitive Guanidines Biochemistry Steroid Mice chemistry.chemical_compound Endocrinology Internal medicine medicine Animals Receptors Histamine H2 Cimetidine Chemistry Uterus Biochemistry (medical) Dihydrotestosterone Androgen receptor Kinetics Steroid hormone Receptors Estrogen Receptors Androgen Estrogen Receptors Histamine Female Histamine Hormone medicine.drug |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 48:189-191 |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jcem-48-2-189 |
| Popis: | The histamine H2 receptor antagonist cimetidine is in increasing usage in the medical management of peptic ulcer. In clinical trials, its most frequent side effect is gynecomastia. Such estrogenic/antiandrogenic manifestations are well known side effects of treatment with digitoxin or spirolactones. Both of these drugs share a common skeleton with the steroid hormones and have been shown to occupy estrogen and/or androgen receptors. Cimetidine has no measurable affinity for rat uterine estradiol receptors, but competes for tritiated dihydrotestosterone-binding sites in mouse kidney preparations with a displacement curve parallel to that for unlabeled dihydrotestosterone. Steroid receptor-mediated side effects, therefore, may not be confined to molecules with a common skeleton, such as steroids, spirolactones, and cardiac glycosides, but may extend to such apparently unrelated molecules as histamine antagonists and androgens. (J Clin Endocrinol Metab 48: 189, 1979) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|